EP3038654
Ný notkun
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
26.8.2014EP published:
30.10.2019EP application number:
14761702.1
EP translation filed:
13.1.2020Grant published:
15.2.2020EPO information:
European Patent Register
Max expiry date:
25.8.2034Expiry date:
25.8.2025
Title:
NEW USE
Timeline
Today
26.8.2014EP application
30.10.2019EP Publication
13.1.2020Translation submitted
15.2.2020Registration published
25.8.2025Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
SHI, Victor ChengweiAddress:
East Hanover, New Jersey, US
Name:
LEFKOWITZ, MartinAddress:
East Hanover, New Jersey, US
Name:
RIZKALA, Adel RemondAddress:
East Hanover, New Jersey, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
PCT/US2013/056680Date:
26.8.2013Country:
WO
Number:
201461972933 PDate:
31.3.2014Country:
US
Classification
Categories:
A61K 45/06, A61K 31/194, A61K 31/197, A61K 31/216, A61K 31/41, A61K 31/221, A61P 9/12, A61P 9/10, A61K 31/401, A61K 9/00, A61K 31/225
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 24.7.2020
Expires: 25.8.2021
Payer: Árnason Faktor ehf.
Number: 8
Paid: 23.7.2021
Expires: 25.8.2022
Payer: Árnason Faktor ehf.
Number: 9
Paid: 27.7.2022
Expires: 25.8.2023
Payer: Árnason Faktor ehf.
Number: 10
Paid: 26.7.2023
Expires: 25.8.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 23.7.2024
Expires: 25.8.2025
Payer: Árnason Faktor ehf.